Article

p53 mutation heterogeneity in cancer

Laboratoire de Génotoxicologie des tumeurs, EA3493 IC-UPMC, Hôpital Tenon, Dpt Pneumologie, 26 rue d'Ulm, 75005 Paris, France.
Biochemical and Biophysical Research Communications (Impact Factor: 2.3). 07/2005; 331(3):834-42. DOI: 10.1016/j.bbrc.2005.03.190
Source: PubMed

ABSTRACT

The p53 gene is inactivated in about 50% of human cancers and the p53 protein is an essential component of the cell response induced by genotoxic stresses such as those generated by radiotherapy or chemotherapy. It is therefore highly likely that these alterations are an important component in tumor resistance to therapy. The particular characteristics of these alterations, 80% of which are missense mutations leading to functionally heterogeneous proteins, make p53 a unique gene in the class of tumor suppressor genes. A considerable number of mutant p53 proteins probably have an oncogenic activity per se and therefore actively participate in cell transformation. The fact that the apoptotic and antiproliferative functions of p53 can be dissociated in certain mutants also suggests another level of complexity in the relationships between p53 inactivation and neoplasia.

Download full-text

Full-text

Available from: Thierry Soussi, Nov 18, 2015
  • Source
    • "The tumor suppressor TP53 (p53) is inactivated or mutated in multiple cancers, including B-cell lymphoma [1]. P53 action in response to DNA damage most often occurs by the activation of genes involved in cell-cycle arrest, senescence, and apoptosis [2]. "

    Full-text · Article · Feb 2016
  • Source
    • "The incidence of bladder cancer is strongly associated with occupational exposure, tobacco smoking, lifestyle habits such as coffein intake, artificial sweeteners, and hair dyes. On the other hand, m olecular factors alterations like p53, Rb, p21, p27, p16 contribute to bladder cancer risk (Buyru et al., 2003; Soussi and Lozano, 2005; Crawford, 2008; Colombel 2008; Akca and Tokgun, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to determine whether endothelial nitric oxide synthase (eNOS) gene polymorphisms play a role in development of bladder cancer in the Turkish population. The study was performed on 75 patients (64 men, 11 women) with bladder cancer and 143 healthy individuals (107 men, 36 women) with any kind of cancer history. Three eNOS gene polymorphisms (T-786C promoter region, G894T and intron 4 VNTR 4a/b) were determined with polymerase chain reaction and restriction fragment lenght polymorphism methods. In our study, GT and TT genotypes for eNOS G894T polymorphism were found to significantly vary among patients with bladder cancer and control group (OR: 0.185, CI: 0.078-0.439, p=0.0001 and OR: 0.324, CI: 0.106-0.990, p=0.026). Also, the frequency of the 894T allele was significantly higher in patients with bladder cancer (51%). No association was identified for eNOS T-786C and intron 4 VNTR 4a/b polymorphisms between patients with bladder cancer and control groups in our Turkish population.
    Full-text · Article · Apr 2015 · Asian Pacific journal of cancer prevention: APJCP
  • Source
    • "The incidence of bladder cancer is strongly associated with occupational exposure, tobacco smoking, lifestyle habits such as coffein intake, artificial sweeteners, and hair dyes. On the other hand, m olecular factors alterations like p53, Rb, p21, p27, p16 contribute to bladder cancer risk (Buyru et al., 2003; Soussi and Lozano, 2005; Crawford, 2008; Colombel 2008; Akca and Tokgun, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to determine whether endothelial nitric oxide synthase (eNOS) gene polymorphisms play a role in development of bladder cancer in the Turkish population. The study was performed on 75 patients (64 men, 11 women) with bladder cancer and 143 healthy individuals (107 men, 36 women) with any kind of cancer history. Three eNOS gene polymorphisms (T-786C promoter region, G894T and intron 4 VNTR 4a/b) were determined with polymerase chain reaction and restriction fragment lenght polymorphism methods. In our study, GT and TT genotypes for eNOS G894T polymorphism were found to significantly vary among patients with bladder cancer and control group (OR: 0.185, CI: 0.078-0.439, p=0.0001 and OR: 0.324, CI: 0.106-0.990, p=0.026). Also, the frequency of the 894T allele was significantly higher in patients with bladder cancer (51%). No association was identified for eNOS T-786C and intron 4 VNTR 4a/b polymorphisms between patients with bladder cancer and control groups in our Turkish population.
    Full-text · Article · Mar 2015 · Asian Pacific journal of cancer prevention: APJCP
Show more